**Highlights of This Issue**

**SPECIAL FEATURES**

**CCR 20th Anniversary Commentary**

3  *Clinical Cancer Research: The 20th Anniversary*

**CCR Translations**

4  Bromodomain Inhibition in Diffuse Large B-cell Lymphoma—Giving MYC a Brake
   Anja Mottok and Randy D. Gascoyne
   See related article, p. 113

7  New, Tolerable γ-Secretase Inhibitor Takes Desmoid Down a Notch
   Dennis P. M. Hughes, Shivaani Kummar, and Alexander J. Lazar
   See related article, p. 60

**CCR New Strategies**

10 New Strategies in Renal Cell Carcinoma: Targeting the Genetic and Metabolic Basis of Disease
   Ramaprasad Srinivasan, Christopher J. Ricketts, Carole Sourbier, and W. Marston Linehan

**Molecular Pathways**

18 Molecular Pathways: Not a Simple Tube—The Many Functions of Blood Vessels
   Brent A. Orr and Charles G. Eberhart

24 Molecular Pathways: Targeting the Kinase Effectors of RHO-Family GTPases
   Tatiana Y. Prudnikova, Sonali J. Rawat, and Jonathan Chernoff

**CANCER THERAPY: CLINICAL**

39 Tadalafil Reduces Myeloid-Derived Suppressor Cells and Regulatory T Cells and Promotes Tumor Immunity in Patients with Head and Neck Squamous Cell Carcinoma
   Donald T. Weed, Jennifer L. Vella, Isidirinha M. Reis, Adriana C. De la fuente, Carmen Gomez, Zouakia Sargi, Ronen Nazarian, Joseph Califano, Ivan Borrello, and Paolo Serafini

49 Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial
   Serena Di Cosimo, Sristam Sathyanarayanan, Johanna C. Bendell, Andrés Cervantes, Mark N. Stein, Irene Bria, Desamparados Rosta, Brian B. Haines, Theresa Zhang, Christopher G. Winter, Sharda Iha, Youyuan Xu, Jason Frazier, Richard A. Klinghoffer, Ann Leighton-Swayne, Yang Song, Scot Ebbehaus, and José Baselga

60 A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014
   See related commentary, p. 7

68 A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis
   Kim A. Reiss, Joseph M. Herman, Marianna Zahurak, Anthony Brade, Laura A. Dawson, Angela Scardina, Caitlin Joffe, Emily Petito, Amy Hacker-Prietz, Robert J. Kinders, Liuwa Wang, Alice Chen, Sarah Temkin, Naomi Horiba, Lillian L. Sui, and Niolofer A. Azad

77 First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
   Debashis Sarker, Joo Eun Ang, Richard Baird, Rebecca Kistelei, Krupal Shah, Victor Moreno, Paul A. Clarke, Florence J. Raynald, Gallia Levy, Joseph A. Ware, Kathlyn Mazina, Raymond Lin, Jenny Wu, Jill Fredrickson, Jill M. Sporke, Mark R. Lackner, Yihing Yan, Lori S. Friedman, Stan B. Kaye, Mika K. Derynck, Paul Workman, and Johann S. de Bono
The Ability of Bilirubin in Identifying Smokers with Higher Risk of Lung Cancer: A Large Cohort Study in Conjunction with Global Metabolomic Profiling
Chi-Pang Wen, Fanmao Zhang, Dong Liang, Christopher Wen, Jian Gu, Heath Skinner, Wong-Ho Chow, Yuanqing Ye, Xia Pu, Michelle A.T. Hildebrandt, Maosheng Huang, Chien-Hua Chen, Chao Agnes Hsiung, Min Kuang Tsai, Chwen Keng Tsao, Scott M. Lippman, and Xifeng Wu

Activation of IL6/IGFIR Confers Poor Prognosis of HBV-Related Hepatocellular Carcinoma through Induction of OCT4/NANOG Expression
Te-Sheng Chang, Yu-Chih Wu, Ching-Chi Chi, Wei-Chi Su, Pey-Jium Chang, Kam-Fai Lee, Tao-Hsin Tung, Jui Wang, Jun-Jen Liu, Shui-Yi Tung, Liang-Mou Kuo, Hong-Nerng Ho, Thai-Yen Ling, and Yen-Hua Huang

Effects of BRCA1- and BRCA2-Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis
Qian Zhong, Hong-Ling Peng, Xia Zhao, Lin Zhang, and Wei-Ting Hwang

LETTERS TO THE EDITOR

Diffusion-Weighted MRI for Lymphoma Staging—Letter
Hugo J.A. Adams and Thomas C. Kwee

Diffusion-Weighted MRI for Lymphoma Staging—Response
Marius E. Mayerhoefer and Markus Raderer

ABOUT THE COVER

The cover shows the results of an unsupervised two-dimensional hierarchical clustering analysis of the 5,000 most variable genes classifying breast tumors into ER⁺, HER2⁺, or triple-negative (ER⁻, PR⁻, HER2⁻) subtypes. The analysis was performed on 800 breast tumors obtained from the Karolinska Institutet, Sweden. The RAS gene expression signature was high in the triple-negative subtype and low in the ER⁺ subtype. For details, see the article by Di Cosimo and colleagues on page 49 of this issue.
Clinical Cancer Research

21 (1)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/21/1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.